Congenital adrenal hyperplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Undo revision 1465293 by Mehrian.jafari (talk))
 
(196 intermediate revisions by 12 users not shown)
Line 1: Line 1:
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
 
{{Infobox_Disease |
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], [[congenital lipoid adrenal hyperplasia]]'''.
  Name          = Congenital adrenal hyperplasia |
 
  Image          = Cortisol2_svg.png  |
<div style="-webkit-user-select: none;">
  Caption        = [[Cortisol]] |
__NOTOC__
  DiseasesDB    = 1854 |
{{Infobox Disease
  DiseasesDB_mult = {{DiseasesDB2|1832}} {{DiseasesDB2|4}} {{DiseasesDB2|1841}} {{DiseasesDB2|2565}}  |
| Name = Adrenal insufficiency
  ICD10          = {{ICD10|E|25|0|e|20}} |
| Image = Illu adrenal gland.jpg
  ICD9          = {{ICD9|255.2}} |
| Caption = Adrenal gland
  ICDO          = |
  OMIM          = 201910 |
  OMIM_mult      = {{OMIM2|201710}} {{OMIM2|202110}} {{OMIM2|201810}} {{OMIM2|202010}}|
  MedlinePlus    = 000411 |
  eMedicineSubj  = ped |
  eMedicineTopic = 48 |
  MeshID        = D000312 |
}}
}}
{{Search infobox}}
{{Congenital adrenal hyperplasia}}
{{CMG}}
 
__NOTOC__
{{CMG}}; {{AE}}{{MJ}}
'''Associate Editor-In-Chief:''' {{CZ}}
 
{{SK}} Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.
 
==Overview==
==Overview==
'''Congenital adrenal hyperplasia''' ('''CAH''') refers to any of several [[autosomal]] [[recessive]] conditions resulting from biochemical paths of the [[steroidogenesis]] of [[cortisol]] from [[cholesterol]] by the [[adrenal gland]]s.
Congenital adrenal hyperplasia consists of several disorders resulting from defective [[enzymes]] and [[proteins]] involved in [[steroid]] and [[cortisol]] synthesis pathways. Defects in [[steroid]] [[biosynthesis]] are caused by several [[genetic mutations]] and may lead to [[delayed puberty]], [[precocious puberty]] or [[ambiguous genitalia]] in specific disorders. The decrease in [[cortisol]] level leads to the release of the inhibitory feedback on [[corticotropin]] ([[ACTH]]) production. The high [[ACTH]] level causes increase [[cortisol]] precursors and overproduction of other [[hormones]]. The most common cause of congenital adrenal hyperplasia is a [[21-hydroxylase deficiency]], which accounts for more than 95% of cases. Other causes include [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], [[3 beta-hydroxysteroid dehydrogenase deficiency]], [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]], and [[congenital lipoid adrenal hyperplasia]].
Most of these conditions involve greater or lesser production of [[sex steroid]]s and can alter development of [[primary sex characteristic|primary]] or [[secondary sex characteristic]]s in affected infants, children, and adults. Only a small minority of people with CAH can be said to have an [[intersex]] condition, but this attracted American public attention in the late 1990s and many accounts of varying accuracy have appeared in the popular media. Approximately 95% of cases of CAH are due to [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency|21-hydroxylase deficiency]].


Examples of conditions caused by various forms of CAH:
==Classification==
* [[ambiguous genitalia]], in some females, such that it can be initially difficult to determine sex
Congenital adrenal hyperplasia (CAH) is classified into seven types based on the [[genetic]] causes that lead to [[hyperplasia]] and [[Hormone|hormonal]] imbalance. CAH is [[hyperplasia]] of different layer of [[Adrenal cortex]]. Within the [[adrenal cortex]], there are three layers named zones; each of them has a distinct cell type and secrete specific [[hormones]].
* [[vomiting]] due to [[natriuresis|salt-wasting]] leading to [[dehydration]] and death
==== [[Adrenal cortex]] zones based on the hormonal synthesis ability and location: ====
* early [[pubarche|pubic hair]] and rapid growth in childhood
<div style="-webkit-user-select: none;">
* [[precocious puberty]] or failure of [[puberty]] to occur ([[sexual infantilism]]: absent or [[delayed puberty]])
* Zona glumerulosa:
* [[hirsutism|excessive facial hair]], [[virilization]], and/or [[menstrual cycle|menstrual irregularity]] in adolescence
** The outer layer of [[adrenal cortex|adrenal cortex.]]
* [[infertility]] due to [[anovulation]]
** Laying directly under the [[Adrenal gland|adrenal]] [[capsule]].
* [[hypertension]]  
** Secretion: [[Aldosterone]] synthesis.
* Zona fasciculate:
** The middle part of [[adrenal cortex]]
** Laying under zona glumerulosa
** Secretion: [[Cortisol]] synthesis
* Zona reticularis:
** The inner part of [[adrenal cortex]]
** Laying between zona fasciculate and [[adrenal medulla]]
** Secretion: [[Androgen]] synthesis


==History==
[[image:Adrenal cortex labelled.jpg|600px|center|thumb|[[Adrenal cortex]] zones -  By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551]]
An Italian anatomist, Luigi De Crecchio provided the earliest known description of a case of probable CAH. <blockquote>I propose in this narrative that it is sometimes extremely difficult and even impossible to determine sex during life. In one of the [[anatomy|anatomical]] theaters of the hospital..., there arrived toward the end of January a cadaver which in life was the body of a certain Joseph Marzo... The general physiognomy was decidedly male in all respects. There were no feminine curves to the body. There was a heavy beard. There was some delicacy of structure with muscles that were not very well developed... The distribution of [[pubic hair]] was typical of the male. Perhaps the lower extremities were somewhat delicate, resembling the female, and were covered with hair... The [[penis]] was curved posteriorly and measured 6 cm, or with stretching, 10 cm. The [[glans|corona]] was 3 cm long and 8 cm in circumference. There was an ample [[foreskin|prepuce]]. There was a first grade [[hypospadias]]... There were two folds of skin coming from the top of the penis and encircling it on either side. These were somewhat loose and resembled [[labia majora]].</blockquote> De Crecchio then described the internal organs, which included a normal [[vagina]], [[uterus]], [[fallopian tube|tubes]], and [[ovary|ovaries]]. <blockquote>It was of the greatest importance to determine the habits, tendencies, passions, and general character of this individual... I was determined to get as complete a story as possible, determined to get at the base of the facts and to avoid undue exaggeration which was rampant in the conversation of many of the people present at the time of the dissection.</blockquote> He interviewed many people and satisfied himself that Joseph Marzo "conducted himself within the sexual area exclusively as a male, "even to the point of contracting the "[[syphilis|French disease]]" on two occasions. The cause of death was another in a series of episodes of vomiting and diarrhea.


This account, translated by Alfred Bongiovanni from De Crecchio (Sopra un caso di apparenzi virili in una donna. ''Morgagni'' 7:154-188, 1865), contains nearly all the important themes and issues. Were this man's male [[gender identity]], [[gender role|role]], and [[sexual orientation|orientation]] determined by his anatomy, by his [[testosterone]], or by his [[sex of rearing]]? His presumed female [[chromosome]]s and [[gonad]]s obviously did not make him female. Yet despite his careful documentation of Marzo's unambiguous social role, De Crecchio rejects his male identity and describes him as "una donna," revealing the 19th century assumption that a person's "true sex" can be determined by inspection of internal organs. Then as now, such a case prompted "undue exaggeration" and much "conversation." And then as now, we see the conflict between the desire of the scientist to learn and understand, and the sense of violation of poor Joseph Marzo's privacy. Finally, were the episodes of vomiting and diarrhea the salt-wasting of CAH?
==== Impairment of each pathway and [[enzyme]] may lead to a specific subtype of congenital adrenal hyperplasia include: ====
<div style="-webkit-user-select: none;">
* [[21-hydroxylase deficiency]]
* [[17 alpha-hydroxylase deficiency]]
* [[11β-hydroxylase deficiency]]
* [[3 beta-hydroxysteroid dehydrogenase deficiency]]
* [[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
* [[Congenital lipoid adrenal hyperplasia]]


The association of excessive sex steroid effects with diseases of the adrenal cortex have been recognized for over a century. The term ''adrenogenital syndrome'' was applied to both sex-steroid producing tumors and severe forms of CAH for much of the 20th century, before some of the forms of CAH were understood. '''Congenital adrenal hyperplasia,''' which also dates to the first half of the century, has become the preferred term to reduce ambiguity and to emphasize the underlying pathophysiology of the disorders.
====Adrenal steroid synthesis pathways in adrenal cortex and related enzymes====


Much of our modern understanding and treatment of CAH comes from research conducted at [[Johns Hopkins Medical School]] in Baltimore in the middle of the 20th century. Lawson Wilkins, "founder" of [[pediatric endocrinology]], worked out the apparently paradoxical pathophysiology: that hyperplasia and overproduction of adrenal androgens resulted from impaired capacity for making cortisol. He reported use of adrenal cortical extracts to treat children with CAH in 1950. Genital reconstructive surgery was also pioneered at Hopkins. After application of [[karyotype|karyotyping]] to CAH and other [[intersex]] disorders in the 1950s, [[John Money]], JL Hampson, and JG Hampson persuaded both the scientific community and the public that sex assignment should not be based on any single biological criterion, and gender identity was largely learned and has no simple relationship with chromosomes or hormones. See [[Intersex]] for a fuller history, including recent controversies over reconstructive surgery.
[[image:Adrenal Steroids.png|thumb|800px|center|Adrenal steroid synthesis pathways in adrenal cortex and related enzymes <ref name="urlFile:Adrenal Steroids Pathways.svg - Wikimedia Commons">{{cite web |url=https://commons.wikimedia.org/wiki/File:Adrenal_Steroids_Pathways.svg|title=File:Adrenal Steroids Pathways.svg - Wikimedia Commons |format= |work= |accessdate=}}</ref>]]


[[Hydrocortisone]], [[fludrocortisone]], and [[prednisone]] were available by the late 1950s. By 1980 all of the relevant steroids could be measured in blood by reference laboratories for patient care. By 1990 nearly all specific genes and enzymes had been identified.
==== Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: <ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref>====
<div style="-webkit-user-select: none;">
{| class="wikitable" align="center" style="border: 0px; font-size: 90%; margin: 3px;"
! colspan="2" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and symptoms
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory findings
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Defective gene
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Blood pressure
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Genitalia
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Cortisol
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Androgens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Estrogens
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased hormone precursors
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Potassium levels
|-
| rowspan="3" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[21-hydroxylase deficiency]]
| style="background:#DCDCDC;" |Classic type, salt-wasting
| align="center" style="padding: 5px 5px; background: " |↓
|
* Female: [[Ambiguous genitalia]]


However, the last decade has seen a number of new developments, discussed more extensively in [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency]]:
* Male: Normal or scrotal [[pigmentation]] and large phallus 
# debate over the value of [[genital reconstructive surgery]] and changing standards
| align="center" style="padding: 5px 5px; background: " |↓
# debate over [[sex assignment]] of severely virilized XX infants
| align="center" style="padding: 5px 5px; background: " |↓↓
# new treatments to improve height outcomes
| align="center" style="padding: 5px 5px; background: " |↑
# [[newborn screening]] programs to detect CAH at birth
| align="center" style="padding: 5px 5px; background: " |Relatively low
# increasing attempts to treat CAH before birth
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |↑
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Classic type, non-salt-wasting
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Ambiguous genitalia]]


== Epidemiology and Demographics ==  
* Male: normal or scrotal pigmentation and large phallus
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
| align="center" style="padding: 5px 5px; background: " |Normal
|[[CYP21A1]] and [[CYP21A2]] gene
|-
| style="background:#DCDCDC;" |Non-classic type
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Female: [[Virilization]] after [[puberty]]
* Male: Normal appearance
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] response to [[ACTH]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
[[CYP21A1]] and [[CYP21A2]] gene
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: Normal
* Male: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |Normal [[corticosterone]]
Normal [[cortisol]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Deoxycorticosterone]]
* [[Progesterone]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |[[CYP17A1]]
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↑
|
* Female: [[Ambiguous genitalia]]


* The disorder in the most classical form is thought to affect approximately 1 in 15-30,000 patients.  Milder forms of the disease are estimated to occur in as many as 1 in 100-1000 patients.  90% of CAH is due to a complete or partial deficiency in 21-hyroxylase.  5-8% of CAH is due to deficiency in 11-hydroxylase.  In rare instances, 17-alpha-hydroxylase and 3-beta-hydroxysteroid dehydrogenase deficiency can lead to CAH.  Certain ethnic groups are thought to be at increased risk such as Yupik Eskimos and Jews of Moroccan ancestry.
* Male: Normal or scrotal pigmentation and large [[Phallus (embryology)|phallus]]
* 21-Hydroxylase 
| align="center" style="padding: 5px 5px; background: " |↓
*:* Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol leads to decreased cortisol synthesis and increased ACTH secretion.  The resulting adrenal stimulation leads to increased production of androgens.  Aldosterone secretion is also impaired in some patients.  There are several clinical syndromes based on the degree of enzyme deficiency.  These include the simple virilizing form, salt-wasting form and nonclassical form.
| align="center" style="padding: 5px 5px; background: " |↑
* 11-Hydroxylase
| align="center" style="padding: 5px 5px; background: " |↑
*:* Deficiency of this enzyme leads to excessive production of androgens and mineralocorticoids.  There is excessive production of 11-deoxycorticosterone, which has mineralocorticoid effect, and adrenal androgens.
| align="center" style="padding: 5px 5px; background: " |Relatively low
|
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |CYP11B1
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: " |↓
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |Male:↓
Female:↑
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: " |↑
| align="center" style="padding: 5px 5px; background: " |HSD3B2
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Cytochrome P450-oxidoreductase (POR) deficiency (ORD)]]
| align="center" style="padding: 5px 5px; background: " |Normal
|
* Both male and female: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓


== Pathophysiology & Etiology==  
| align="center" style="padding: 5px 5px; background: " |Normal
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: " |Normal
|[[Mutations]] in the [[flavoprotein]] co-factor of the enzymes [[CYP17A1]], [[CYP21A2]], and [[CYP19A1]] ([[aromatase]]).
|-
| colspan="2" align="center" style="padding: 5px 5px; background: #DCDCDC;" |[[Congenital lipoid adrenal hyperplasia]]
| align="center" style="padding: 5px 5px; background: " |↓
|
* Female: Normal, [[delayed puberty]] in females
* Male: [[Ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |↓
| align="center" style="padding: 5px 5px; background: " |None of precursors increased
| align="center" style="padding: 5px 5px; background: " |↓
|[[Gene mutation|Gene mutations]] on [[Chromosome 8 (human)|chromosome 8]], codes for a [[protein]] called [[steroid]] acute regulatory protein (StAR)
|}


* Simple Virilizing Form 
==Differential Diagnosis==
*:* Female fetuses demonstrate evidence of androgen excess including genital ambiguity.  Precocious puberty, accelerated growth followed by premature growth arrest due to epiphiseal fusion can be noted. Because virilization or androgen excess can be very mild, it can be overlooked until later in life.
Congenital adrenal hyperplasia can present with different symptoms such as:
* Salt-Wasting Form 
* [[Ambiguous genitalia]]
*:* These patients may have virilizing features but 2/3 will also manifest mineralocorticoid deficiency with salt wasting, hyperkalemia, and hypotension, usually within the first 2 weeks of life.
* [[Virilization]] and [[hirsutism]] in female
* Nonclassical Form 
* [[Primary amenorrhea]]
*:* Patients may present with amenorrhea/oligomenorrhea with signs of androgen excess such as hirsutism.  These women usually present around puberty and resemble patients with polycystic ovarian syndrome.
* Low reninemic [[hypertension]]
Differential diagnosis for each of these symptoms are described in below tables.


==Types of CAH==
===[[Congenital adrenal hyperplasia]] must be differentiated from diseases that cause [[ambiguous genitalia]]:<ref name="pmid17875484">{{cite journal |vauthors=Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT |title=Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development |journal=Best Pract. Res. Clin. Endocrinol. Metab. |volume=21 |issue=3 |pages=351–65 |year=2007 |pmid=17875484 |doi=10.1016/j.beem.2007.06.003 |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref>===
[[Image:DHEA1_svg.png|thumb|300px|Production of DHEA from Cholesterol. ([[Cortisol]] is a [[glucocorticoid]].)]]
[[Cortisol]] is an adrenal [[steroid hormone]] necessary for life; production begins in the second month of fetal life. Inefficient cortisol production results in rising levels of [[adrenocorticotropic hormone|ACTH]], which in turn induces overgrowth (''hyperplasia'') and overactivity of the [[steroid]]-producing cells of the adrenal cortex. The defects causing adrenal hyperplasia are ''congenital'' (i.e., present at birth).


Cortisol deficiency in CAH is usually partial, and not the most serious problem for an affected person. Synthesis of cortisol shares steps with synthesis of [[mineralocorticoid]]s such as [[aldosterone]], [[androgen]]s such as [[testosterone]], and [[estrogen]]s such as [[estradiol]]. The resulting excessive or deficient production of these three classes of hormones produce the most important problems for people with CAH. Specific enzyme inefficiencies are associated with characteristic patterns of over- or underproduction of mineralocorticoids or [[sex steroid]]s.
{| class="wikitable"
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Increased
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased
|-
|[[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]]
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[Progesterone]]
* [[Androstenedione]]
* [[DHEA]]
|
* [[Aldosterone]]
* [[Corticosterone]] (salt-wasting)
* [[Cortisol]] ([[virilization]])
|
* [[Ambiguous genitalia]] in female
* [[Virilization]] in female
* Salt-wasting
* [[Hypotension]] and [[hyperkalemia]]
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] (mild elevation)
|
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* [[Ambiguous genitalia]] in female
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|-
|[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
|
* [[Deoxycorticosterone]]
* [[Corticosterone]]
* [[Progesterone]]
|
* [[Cortisol]]
* [[Aldosterone]]
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]


In all its forms, [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency]] accounts for about 95% of diagnosed cases of CAH. Unless another specific enzyme is mentioned, "CAH" in nearly all contexts refers to [[21-hydroxylase]] deficiency.
* [[Primary amenorrhea]]
*Severe 21-hydroxylase deficiency causes '''''salt-wasting CAH''''', with life-threatening vomiting and [[dehydration]] occurring within the first weeks of life. Severe 21-hydroxylase deficiency is also the most common cause of [[ambiguous genitalia]] due to prenatal [[virilization]] of genetically female (XX) infants.
*Moderate 21-hydroxylase deficiency is referred to as '''''simple virilizing CAH'''''; and typically is recognized by causing virilization of prepubertal children.
*Still milder forms of 21-hydroxylase deficiency are referred to as '''''non-classical CAH''''' and can cause [[androgen]] effects and [[infertility]] in adolescent and adult women.


CAH due to deficiencies of enzymes other than 21-hydroxylase present many of the same management challenges as 21-hydroxylase deficiency, but some involve [[mineralocorticoid]] excess or [[sex steroid]] deficiency.
* Absence of [[secondary sexual characteristics]]
*[[Lipoid congenital adrenal hyperplasia]]
*[[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|Congenital adrenal hyperplasia due to 17α-hydroxylase deficiency]]
*[[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|Congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency]]
*[[Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency|Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency]]


Further variability is introduced by the degree of [[enzyme]] inefficiency produced by the specific [[allele]]s each patient has. Some alleles result in more severe degrees of enzyme inefficiency. In general, severe degrees of inefficiency produce changes in the fetus and problems in prenatal or perinatal life. Milder degrees of inefficiency are usually associated with excessive or deficient [[sex steroid|sex hormone]] effects in childhood or adolescence, while the mildest form of CAH interferes with ovulation and [[fertility]] in adults.
* Minimal [[body hair]]
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
|
* [[Cortisol]]
* [[Aldosterone]]
|
* [[Vomiting]], [[volume depletion]], [[hyponatremia]], and [[hyperkalemia]]
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis
|-
| Gestational [[hyperandrogenism]]
| colspan="2" |
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high
* If [[virilization]] is caused by exogenous [[hormone]] administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]]
|
* [[Androgen]] excess in mother
* History of [[androgen]] containing [[medication]]  consumption during [[pregnancy]] in mother
* [[Virilization]] in a 46,XX individual with normal female internal anatomy
* Causes include maternal [[luteoma]] or theca-[[lutein]] [[cysts]], and [[placental]] [[aromatase]] enzyme deficiency
|}


Finally, specific problems may also differ with the genetic [[Gender|sex]] of the affected person. For example, the most common type of CAH, due to deficient 21-hydroxylase activity, can produce [[ambiguous genitalia]] in XX fetuses but not XY.
===Congenital adrenal hyperplasia must be differentiated from diseases that cause [[virilization]] and [[hirsutism]] in female:<ref name="pmid24830586">{{cite journal |vauthors=Hohl A, Ronsoni MF, Oliveira Md |title=Hirsutism: diagnosis and treatment |journal=Arq Bras Endocrinol Metabol |volume=58 |issue=2 |pages=97–107 |year=2014 |pmid=24830586 |doi= |url=}}</ref><ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="ISBN:978-0323297387">{{cite book | last = Melmed | first = Shlomo | title = Williams textbook of endocrinology | publisher = Elsevier | location = Philadelphia, PA | year = 2016 | isbn = 978-0323297387 }}=</ref>===


Treatment of all forms of CAH may include any of:
{| class="wikitable"
# supplying enough [[glucocorticoid]] to reduce hyperplasia and overproduction of [[androgen]]s or [[mineralocorticoid]]s
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
# providing replacement mineralocorticoid and extra salt if the person is deficient
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Steroid status
# providing replacement [[testosterone]] or [[estrogen]] at puberty if the person is deficient
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other laboratory
# additional treatments to optimize growth by delaying puberty or delaying [[bone maturation]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
# [[genital reconstructive surgery]] to correct problems produced by abnormal genital structure
|-
|Non-classic type of [[21-hydroxylase deficiency]]
|Increased:
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] in response to [[ACTH]]  
|
* Low [[testosterone]] levels
|
* No symptoms in infancy and male


All of these management issues are discussed in more detail in [[congenital adrenal hyperplasia due to 21-hydroxylase deficiency]].
* [[Virilization]] in females
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|Increased:
* DOC
* 11-Deoxy-[[Cortisol]]
Decreased:
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
* [[DHEA]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
Decreased:
* [[Cortisol]]
* [[Aldosterone]]
|
* Low [[testosterone]] levels
|
* Salt-wasting [[adrenal crisis]] in infancy


===Genetics===
* Mild [[virilization]] of genetically female infants
All involved [[genes]] are autosomal. See the table under 'Biochemistry' subheading for [[chromosome|chromosomal]] locations.
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.  
|-
|[[Polycystic ovary syndrome ]]
|
* High [[DHEAS]] and [[androstenedione]] levels
|
* Low [[testosterone]] levels
|
* [[Polycystic ovaries]] in sonography
* [[Obesity]]
* [[PCOS]] is the most common cause of [[hirsutism]] in women
* No evidence another diagnosis
|-
|[[Adrenal tumors]]
|
* Variable levels depends on [[tumor]] type
|
* Low [[testosterone]] level
|
* Older age
* Rapidly progressive symptoms
|-
|Ovarian [[virilizing]] tumor
|
* Variable levels depends on [[tumor]] type
|
* [[Testosterone]] is high
|
* Older age
* Rapidly progressive symptoms
|-
|[[Cushing's syndrome]]
|
* Increase [[cortisol]] & metabolites
* Variable other [[steroids]]
|
* Variable [[mineralocorticoid]] excess
|
* [[Cushingoid appearance]]
|-
|[[Hyperprolactinemia]]
|
* Normal levels of most of [[steroids]]
|
* Increased [[prolactin]]
|
* [[Infertility]]
* [[galactorrhea]]
|}


Because they code for [[enzyme]]s with amplifiable activity, noticeable effects only occur in people with two defective [[allele]]s of these [[gene]]s. Hundreds of different allelic [[mutation]]s of these genes have been reported. Nearly always, each parent of an affected person is an unaffected [[heterozygote]] (i.e., [[asymptomatic carrier]] of one defective gene and one normal gene and has no ill effects). Each child of that pair of parents has a 25% chance of being affected, "having CAH". [[Prenatal diagnosis]] and heterozygote detection are now possible.
===Some types of congenital adrenal hyperplasia must be differentiated from diseases with [[primary amenorrhea]]:<ref name="pmid21147889">{{cite journal |vauthors=Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C |title=Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients |journal=J. Clin. Endocrinol. Metab. |volume=96 |issue=2 |pages=296–307 |year=2011 |pmid=21147889 |doi=10.1210/jc.2010-1024 |url=}}</ref><ref name="pmid2164530">{{cite journal |vauthors=Moreira AC, Leal AM, Castro M |title=Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency |journal=J. Clin. Endocrinol. Metab. |volume=71 |issue=1 |pages=86–91 |year=1990 |pmid=2164530 |doi=10.1210/jcem-71-1-86 |url=}}</ref><ref name="pmid999330">{{cite journal |vauthors=Heremans GF, Moolenaar AJ, van Gelderen HH |title=Female phenotype in a male child due to 17-alpha-hydroxylase deficiency |journal=Arch. Dis. Child. |volume=51 |issue=9 |pages=721–3 |year=1976 |pmid=999330 |pmc=1546244 |doi= |url=}}</ref><ref name="pmid226795">{{cite journal |vauthors=Biglieri EG |title=Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome |journal=J. Steroid Biochem. |volume=11 |issue=1B |pages=653–7 |year=1979 |pmid=226795 |doi= |url=}}</ref><ref name="pmid8929268">{{cite journal |vauthors=Saenger P |title=Turner's syndrome |journal=N. Engl. J. Med. |volume=335 |issue=23 |pages=1749–54 |year=1996 |pmid=8929268 |doi=10.1056/NEJM199612053352307 |url=}}</ref><ref name="pmid25813279">{{cite journal |vauthors=Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R |title=Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis |journal=Fertil. Steril. |volume=103 |issue=5 |pages=1297–304 |year=2015 |pmid=25813279 |doi=10.1016/j.fertnstert.2015.01.043 |url=}}</ref><ref name="pmid4432067">{{cite journal |vauthors=Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE |title=Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism |journal=Science |volume=186 |issue=4170 |pages=1213–5 |year=1974 |pmid=4432067 |doi= |url=}}</ref><ref name="pmid11344932">{{cite journal |vauthors=Schnitzer JJ, Donahoe PK |title=Surgical treatment of congenital adrenal hyperplasia |journal=Endocrinol. Metab. Clin. North Am. |volume=30 |issue=1 |pages=137–54 |year=2001 |pmid=11344932 |doi= |url=}}</ref>===


Although mutations leading to the various forms of CAH have been found all over the world, there are substantial differences in the carrier rates of specific abnormal alleles in different regions and ethnic groups.
{| class="wikitable"
|-
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Disease
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + | Cause
! colspan="7" style="background:#4479BA; color: #FFFFFF;" + | Differentiating
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Uterus
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Breast development
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Testosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |FSH
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
* HSD3B2  [[gene]] [[mutation]]
|
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* Mild [[virilization]] in 46,XX individuals
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]] and [[XX]]
|-
|[[17-alpha-hydroxylase deficiency]]
|
* [[CYP17A1|CYP17A1 gene mutation]]
|
* Female [[external genitalia]]


===Biochemistry===
* [[Primary amenorrhea]]
* [[Hypertension]]
* Absence of secondary [[sexual characteristics]]
* Minimal [[body hair]]
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Gonadal dysgenesis]]
|
* Mutations in [[SRY]], FOG2/ZFPM2, and WNT1
|
* Female [[external genitalia]]
* Intact [[Mullerian ducts]]
* Streak [[gonads]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[Testicular regression syndrome]]
|
* Loss of [[testicular]] function and tissue early in development
|
* Female phenotype with atrophic [[Mullerian ducts]].
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[LH receptor|LH receptor defects]]
|
* [[LH receptor]] [[gene]] [[mutation]] on [[chromosome 2]]
|
* Female [[external genitalia]]
* Lack a [[uterus]] and [[fallopian tubes]]
* [[Epididymis]] and [[vas deferens]] may be present
* Laboratory:
** Unresponsiveness to [[hCG]]
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]]
|
* [[Autosomal recessive]]
|
* Female [[external genitalia or ambiguous]]
* Bilateral testes and normal [[testosterone]] formation


{| style="border-collapse:collapse" border=1 cellpadding=5
* Impaired external [[virilization]] during [[embryogenesis]]
|- style="background-color:#ccc"
* Defective conversion of [[testosterone]] to [[DHT]].
| '''Common medical term'''
* [[Testosterone]]:[[DHT]] ratio is >10:1
| '''OMIM no.'''
| align="center" style="padding: 5px 5px; background: " |
| '''Enzyme(s)'''
No
| '''Gene location'''
| align="center" style="padding: 5px 5px; background: " |
| '''Substrate(s)'''
No
| '''Product(s)'''
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
High to normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|-
| [[Congenital adrenal hyperplasia due to 21-hydroxylase deficiency|21-hydroxylase CAH]]
|[[Androgen insensitivity syndrome]] 
| {{OMIM|201910}}
|
| P450c21
* [[Androgen receptor]] defect
| 6p21.3
|
| 17OH-progesterone→<br/>[[progesterone]]→
* Female [[external genitalia]]
| 11-deoxycortisol<br/>[[11-deoxycorticosterone|DOC]]
* Resistant to [[testosterone]]
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal male range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
|-
|-
| [[Lipoid congenital adrenal hyperplasia|lipoid CAH]]<br/>(20,22-desmolase)
|[[Mullerian agenesis]]
| {{OMIM|201710}}
|
| StAR<br/>P450scc
* Mutations in ''[[WNT4]]''
| 8p11.2<br/>15q23-q24
|
| transport of [[cholesterol]]<br/>[[cholesterol]]
* Normal female [[genitalia]]
| into mitochondria<br/>[[pregnenolone]]
* Normal [[breast]] development
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|-
| [[Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency|17α-hydroxylase CAH]]
|[[Ovarian insufficiency|Primary ovarian insufficiency]]
| {{OMIM|202110}}
|
| P450c17
* [[Genetic defects]] such as [[turner syndrome]], [[fragile X syndrome]], some other chromosomal defects
| 10q24.3
|
| [[pregnenolone]]→<br/>[[progesterone]]→<br/>17OH-pregnenolone→
* Normal [[female genitalia]]
| 17OH-pregnenolone<br/>17OH-progesterone<br/>[[DHEA]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal female range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|-
| [[Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency|3β-HSD CAH]]
|[[Hypogonadotropic hypogonadism]]
| {{OMIM|201810}}
|
| 3βHSD II
* Functional, sellar masses
| 1p13
|
| [[pregnenolone]]→<br/>17OH-pregnenolone→<br/>[[DHEA]]
* Normal [[female genitalia]],
| [[progesterone]]<br/>17OH-progesterone<br/>[[androstenedione]]
 
* Delayed [[puberty]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
No
| align="center" style="padding: 5px 5px; background: " |
Normal female range
| align="center" style="padding: 5px 5px; background: " |
Low
| align="center" style="padding: 5px 5px; background: " |
Normal
| align="center" style="padding: 5px 5px; background: " |
[[XX]]
|-
|-
| [[Congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency|11β-hydroxylase CAH]]
| align="center" style="padding: 5px 5px; background: " |
| {{OMIM|202010}}
[[Turner syndrome]]
| P450c11β
|
| 8q21-22
* Chromosomal
| 11-deoxycortisol→<br/>DOC→
|
| [[cortisol]]<br/>[[corticosterone]]
* Normal female [[external genitalia]]
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Yes
| align="center" style="padding: 5px 5px; background: " |
Normal [[female]] range
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[Turner syndrome|45 XO]]
|}
|}


Abbreviations:
=== [[17 alpha-hydroxylase deficiency]] and [[11β-hydroxylase deficiency]] can cause low reninemic [[hypertension]] and should be differentiate from other causes of [[pseudohyperaldosteronism]] (low renin): ===
* OMIM no. is [[Online Mendelian Inheritance in Man]] index number
{| class="wikitable"
* StAR is [[steroidogenic acute regulatory protein]]
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pseudohyperaldosteronism causes
* HSD is hydroxysteroid dehydrogenase.
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
* P450scc is [[cytochrome]] P450 [[side chain]] cleavage enzyme.
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
* 17OH-progesterone and 17OHP are [[17-hydroxyprogesterone]].
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical features
* 17OH-pregnenolone is [[17-hydroxypregnenolone]]
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Labratory
* DHEA is [[dehydroepiandrosterone]].
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Treatment
* DOC is [[deoxycorticosterone]].
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Elevated mineralocorticoid
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Renin
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Aldosterone
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
|-
| rowspan="9" |Endogenous causes
|[[17 alpha-hydroxylase deficiency]]
|Mutations in the [[CYP17A1]] gene
|
* [[Ambiguous genitalia]] in male
* [[Hypertension]]


Since the 1960s most endocrinologists have referred to the forms of CAH by the traditional names in the left column, which generally correspond to the deficient enzyme activity. As exact structures and genes for the enzymes were identified in the 1980s, most of the enzymes were found to be [[cytochrome P450 oxidase]]s and were renamed to reflect this. In some cases, more than one enzyme was found to participate in a reaction, and in other cases a single enzyme mediated in more than one reaction. There was also variation in different tissues and mammalian species.
* [[Primary amenorrhea]]


== Diagnosis ==
* Absence of [[secondary sexual characteristics]]


Prenatal diagnosis can be made in both of these disorders by chorionic villous sampling, but this can only be done at 8-10 weeks.  In order to prevent the deleterious effect of excess androgens on genital (and brain!) development, therapy must be started earlier.  This is most often considered if there is an affected sibling.  Treatment is dexamethasone, which is not degraded by the placenta, but is associated with significant maternal weight gain, hypertension, and edema.
* Minimal [[body hair]]
| rowspan="2" |[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
| rowspan="2" |↓
| rowspan="2" |↓
|[[Cortisol]] ↓
| rowspan="2" |[[Corticosteroids]]
|-
|[[11β-hydroxylase deficiency]]
|Mutations in the [[CYP11B1]] gene
|
* [[Ambiguous genitalia]] in female


=== History and Symptoms ===
* [[Hypertension]] and [[hypokalemia]]
* [[Virilization]]
|[[Cortisol]] ↓
|-
|Apparent mineralocorticoid excess syndrome (AME)
|Genetic or acquired defect of 11-HSD gene
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors
|
* Severe juvenile [[hypertension]]
* [[Hypercalciuria]], [[nephrocalcinosis]], [[polyuria]] (due to [[hypokalemia]]-induced [[nephrogenic diabetes insipidus]])
* [[Renal failure]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|↓
|Urinary free [[cortisone]] ↓↓
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers
|-
|[[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1)
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]]
|
* [[Hypertension]]


* 11-Hydroxylase
* [[Hypokalemia]]
*:* The clinical manifestations are of .  The virilization of neonates may be mild or as severe as 21-hydroxylase deficiencies.  The remainder of patients present with precocious puberty and acne in men, or with hirsutism and menstrual irregularities in women.  Hypertension and hypokalemia are present in 2/3 and help distinguish from 21-hydroxylase deficiencies. 
|No extra [[mineralocorticoid]] presents, and mutations in [[Sodium|Na]] channels mimic [[aldosterone]] mechanism
|↓
|↓
|[[Cortisol]] ↓
|[[Amiloride]] or [[triamterene]]
|-
|[[Cushing’s syndrome]]
|
* The main pathogenetic mechanism is linked to the excess
of [[cortisol]] which saturates 11-HSD2 activity,
* This allows [[cortisol]] to bind [[mineralocorticoid receptor]]
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity


=== Physical Examination ===
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
|Urinary free [[cortisol]] markedly ↑↑
|
* [[Pasireotide]], [[Cabergoline]], [[Ketoconazole]], and [[Metyrapone]]


[[Hypertension]] may be present
* Adrenalectomy
|-
|Insensitivity to [[glucocorticoids]] (Chrousos syndrome)
|Mutations in [[glucocorticoid receptor]] (GR) gene
|
* [[Hypertension]]


==== Appearance of the Patient ====
* Adrenal [[hyperandrogenism]]
[[Hirsuitism]] may be present
|[[Deoxycorticosterone]] ([[Deoxycorticosterone|DOC]])
|↓
|↓
|[[Cortisol]]
|[[Dexamethasone]]
|-
|[[Cortisol]]-secreting adrenocortical [[carcinoma]]
|Multifactorial
|
Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* Excess [[sweating]]
* [[Headache]]
|[[Cortisol]] has [[mineralocorticoid]] effects
|↓
|
* ↓ if excess [[cortisol]] saturates 11-HSD2 enzyme activity


==== GU ====
* ↑ in direct activation of [[renin]] [[angiotensin]] system activation by [[glucocorticoids]]
Ambiguous genitalia in females and penile enlargement in males
|Urinary free [[cortisol]] markedly ↑↑
|[[Surgery]]
|-
|Geller’s syndrome
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR
|Severe [[hypertension]] particularly during [[pregnancy]]
|[[Progesterone]] has [[mineralocorticoid]] effects
|↓
|↓
| -
|[[mineralocorticoid]] blockers
|-
|Gordon’s syndrome (Pseudohypoaldosteronism type 2)
|Mutations of at least four genes have been identified, including WNK1 and WNK4
|
* [[Hypertension]]


=== Laboratory Findings ===
* [[Hyperkalemia]]


==== Electrolyte and Biomarker Studies ====
* Normal renal function
In 11-hydroxylase deficiencis, hypokalemia is present in 2/3 and help distinguish from 21-hydroxylase deficiencies.
|No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule
|↓
|Normal
|Hyperkalemia
|thiazide diuretics and/or dietary sodium restriction
|-
| rowspan="4" |Exogenous causes
|Corticosteroids with mineralocorticoid activity
|Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone,
|
* [[Hypertension]]


== Treatment==
* [[Hypokalemia]]
|Medications such as fludrocortisone
|↓
|↓
| -
|Change the treatment
|-
|Licorice ingestion
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]]
|
* [[Hypertension]]


=== Acute Pharmacotherapies ===
* [[Hypokalemia]]
|<nowiki>-</nowiki>
|↓
|↓
|Urinary free cortisol Moderate ↑
|Discontinue licorice
|-
|Grapefruit
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|
* [[Hypertension]]
| -
|↓
|↓
| -
|Discontinue grapefruit
|-
|[[Estrogens]]
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]
|
* [[Hypertension]]


* 21-Hydroxylase
* [[Headache]]
*:* Treatment is aimed at decreasing the drive to produce ACTH (AdrenoCorticoTropic Hormone), thereby decreasing androgen secretion.  Glucocorticoids are given usually as hydrocortisone 25 mg QD in divided doses.  The dose of steroids must be carefully titrated so that androgen production is minimized, but growth inhibition and Cushing’s syndrome from glucocorticoid excess is avoided.  Assessing bone age and growth rate, signs of androgen excess and menstrual cycling gauge response to therapy.  Adjunctive therapy with flutamide, an anti-androgen and testolactone, and anti-aromatase, have been shown to minimize the effects of excess androgens, reduce the dose of glucocorticoids and normalize growth rates. 
* [[Edema]]
*:* Mineralocorticoids, with or without evidence of evidence of salt loss, should be given in the form of fludrocortisone.  It decreases excessive renin and Angiotensin II  (AII) production.  AII stimulates early steps in the steroidogenic pathway and leads to more androgen production.  Both renin and AII are elevated in the salt-wasting and virilizing forms of CAH.  The usual adult dose is 0.1 mg/day.
* [[Weight gain]]
* 11-Hydroxylase
|<nowiki>-</nowiki>
*:* Treatment is similar to 21-hydroxylase deficiency with glucocorticoid replacement.  Clinical assessment of virilization, growth velocity, hair growth, menstrual function and blood pressure are necessary.  Despite adequate glucocorticoid replacement, medication may be required to control blood pressure.  Spironolactone is a good choice as well as calcium blockers.
|↓
|↓
| -
|Discontinue [[estrogens]]
|}


==References==
==== CAH must be differentiated from other causes of irregular menses and [[hirsutism]]: ====
{{Reflist}}
{| class="wikitable"
!Disease
!Differentiating Features
|-
|[[Pregnancy]]
|
* Pregnancy always should be excluded in a patient with a history of [[amenorrhea]]


==See also==
* Features include amenorrhea or [[oligomenorrhea]], abnormal [[uterine bleeding]], [[Nausea and vomiting|nausea/vomiting]], cravings, [[weight gain]] (although not in the early stages and not if vomiting), [[polyuria]], [[abdominal cramps]] and [[constipation]], [[fatigue]], [[dizziness]]/[[lightheadedness]], and [[Hyperpigmentation|increased pigmentation]] (moles, [[nipples]])
*[[Ambiguous genitalia]]
*[[Female pseudohermaphroditism]]  
*[[Adrenal insufficiency]]


==External links==
* [[Uterus|Uterine]] enlargement is detectable on [[abdominal examination]] at approximately 14 weeks of [[gestation]]
* [http://www.caresfoundation.org CARES Foundation: Congenital Adrenal Research, Education, and Support]
* [http://congenitaladrenalhyperplasia.org CongenitalAdrenalHyperplasia.org]
* [http://www.dshs.state.tx.us/newborn/hand_cah.shtm Congenital Adrenal Hyperplasia: A Handbook for Parents]
* [http://www.dshs.state.tx.us/newborn/cahbroch.shtm The ABC's of Congenital Adrenal Hyperplasia]
* [http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Adrenal%20Hyperplasia%2C%20Congenital%20%28General%29|National Organization for Rare Disorders (NORD): Adrenal Hyperplasia, Congenital]
* [http://www.hopkinsmedicine.org/pediatricendocrinology/cah/index.html Guide to Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency for parents or patients from Johns Hopkins]
* [http://www.endotext.org/pediatrics/pediatrics8a/pediatricsframe8a.htm A more advanced discussion of 21-hydroxylase deficiency by an eminent researcher of the disease.]
* [http://magicfoundation.org/www/docs/100/congenital_adrenal_hyperplasia.html MAGIC Foundation: Family Support, Annual Convention with Families and Medical Experts]
{{SIB}}
{{Endocrine pathology}}


[[Category:Pediatrics]]
* [[Ectopic pregnancy]] may cause oligomenorrhea, amenorrhea, or abnormal uterine bleeding with [[abdominal pain]] and sometimes subtle or absent physical symptoms and signs of [[pregnancy]]
[[Category:Endocrinology]]
|-
[[Category:Genetic disorders]]
|Hypothalamic amenorrhea
[[Category:Intersexuality]]
|
[[Category:Mature chapter]]
* Diagnosis of exclusion
* Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue [[stress]] or [[anxiety]]
* Predisposing features are as follows [[weight loss]], particularly if features of [[anorexia nervosa]] are present or the [[BMI]] is <19 kg/m2
* Recent administration of depot [[Medroxyprogesterone acetate|medroxyprogesterone]], which may suppress [[ovarian]] activity for 6 months to a year
* Use of [[dopamine agonists]] (eg, antidepressants) and major [[tranquilizers]]
* [[Hyperthyroidism]]
* In patients with weight loss related to anorexia nervosa, fine hair growth ([[lanugo]]) may occur all over the body, but it differs from [[hirsutism]] in its fineness and wide distribution
|-
|[[Primary amenorrhea]]
|
* Causes include [[reproductive system]] abnormalities, [[chromosomal]] abnormalities, or [[delayed puberty]]
* If [[secondary sexual characteristics]] are present, an [[anatomic]] abnormality (eg, [[imperforate hymen]], which is rare) should be considered
* If secondary sexual characteristics are absent, a chromosomal abnormality (eg, [[Turner syndrome]] ) or [[delayed puberty]] should be considered
|-
|[[Cushing's syndrome|Cushing syndrome]]
|
* [[Cushing syndrome]] is due to excessive [[glucocorticoid]] secretion from the [[adrenal glands]], either primarily or secondary to stimulation from [[Pituitary gland|pituitary]] or ectopic hormones; can also be caused by exogenous [[steroid]] use


[[de:Adrenogenitales Syndrom]]
* Features include [[hypertension]], [[weight gain]] (central distribution), [[acne]], and abdominal striae Patients have [[Hyponatremia|low plasma sodium levels]] and elevated plasma cortisol levels on [[dexamethasone]] suppression testing
[[es:Hiperplasia suprarrenal congénita]]
|-
[[it:Iperplasia surrenale congenita]]
|[[Hyperprolactinemia]]
[[nl:Adrenogenitaal syndroom]]
|
* Mild [[hyperprolactinemia]] may occur as part of [[PCOS]]-related hormonal dysfunction
 
* Other causes include [[stress]], [[lactation]], and use of [[dopamine antagonists]]
* A [[prolactinoma]] of the [[pituitary gland]] is an uncommon cause and should be suspected if [[prolactin]] levels are very high (>200 ng/mL)
* Physical examination findings are usually normal
* As in patients with PCOS, hyperprolactinemia may be associated with mild [[galactorrhea]] and [[oligomenorrhea]] or [[amenorrhea]]; however, galactorrhea also can occur with [[nipple]] stimulation and/or [[stress]] when prolactin levels are within normal ranges
* A large [[prolactinoma]] may cause [[headaches]] and [[visual field]] disturbance due to pressure on the [[optic chiasm]], classically a gradually increasing bi-temporal hemianopsia
|-
|Ovarian or adrenal tumor
|
* Benign [[Ovarian tumor|ovarian tumors]] and ovarian cancer are rare causes of excessive [[androgen]] secretion; [[adrenocortical]] [[tumors]] also can increase the production of [[sex hormones]]
* [[Abdominal swelling]] or [[mass]], [[abdominal pain]] due to fluid leakage or [[torsion]], [[dyspareunia]], abdominal [[ascites]], and features of [[metastatic]] disease may be present
* Features of androgenization include [[hirsutism]], [[weight gain]], [[oligomenorrhea]] or [[amenorrhea]], [[acne]], [[clitoral hypertrophy]], deepening of the voice, and high [[Androgen|serum androgen]] (eg, [[testosterone]], other androgens) levels
* In patients with an androgen-secreting tumor, serum testosterone is not suppressed by [[dexamethasone]]
|-
|[[Congenital adrenal hyperplasia]]
|
* Congenital adrenal hyperplasia is a rare [[genetic]] condition resulting from 21-hydroxylase deficiency
* The late-onset form presents at or around menarche Patients have features of androgenization and [[subfertility]]
* Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
* Associated with high levels of [[17-hydroxyprogesterone]]
* A short [[adrenocorticotropic hormone]] stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to [[21-hydroxylase deficiency]]
|-
|Anabolic steroid abuse
|
* [[Anabolic steroid|Anabolic steroids]] are synthetic hormones that imitate the actions of [[testosterone]] by increasing [[muscle]] bulk and strength
* Should be considered if the patient is a serious sportswoman or bodybuilder
* Features include [[virilization]] (including [[acne]] and [[hirsutism]]), often increased muscle bulk in male pattern, [[oligomenorrhea]] or [[amenorrhea]], [[clitoromegaly]], [[gastritis]], [[hepatomegaly]], [[alopecia]], and aggression
* Altered [[liver function test]] results are seen
|-
|[[Hirsutism]]
|
* [[Hirsutism]] is excessive facial and body hair, usually coarse and in a male pattern of distribution
* Approximately 10% of women report unwanted facial hair
* There is often a family history and typically some Mediterranean or Middle Eastern ancestry
* May also result from use of certain [[medications]], both [[androgens]], and others including [[danazol]], [[glucocorticoids]], [[cyclosporine]], and [[phenytoin]]
* [[Menstrual cycle|Menstrual]] history is normal
* When the cause is [[Genetics|genetic]], the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
* When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as [[acne]] and deepened voice, may be present
|}


{{WikiDoc Help Menu}}
==References==
{{WikiDoc Sources}}
{{reflist|2}}

Latest revision as of 15:57, 23 April 2018

This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia.

Adrenal insufficiency
Adrenal gland

Congenital adrenal hyperplasia main page

Overview

Classification

21-hydroxylase deficiency
11β-hydroxylase deficiency
17 alpha-hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Lipoid congenital adrenal hyperplasia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: Congenital adrenal hyperplasia; CAH; Adrenal hyperplasia.

Overview

Congenital adrenal hyperplasia consists of several disorders resulting from defective enzymes and proteins involved in steroid and cortisol synthesis pathways. Defects in steroid biosynthesis are caused by several genetic mutations and may lead to delayed puberty, precocious puberty or ambiguous genitalia in specific disorders. The decrease in cortisol level leads to the release of the inhibitory feedback on corticotropin (ACTH) production. The high ACTH level causes increase cortisol precursors and overproduction of other hormones. The most common cause of congenital adrenal hyperplasia is a 21-hydroxylase deficiency, which accounts for more than 95% of cases. Other causes include 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), and congenital lipoid adrenal hyperplasia.

Classification

Congenital adrenal hyperplasia (CAH) is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. CAH is hyperplasia of different layer of Adrenal cortex. Within the adrenal cortex, there are three layers named zones; each of them has a distinct cell type and secrete specific hormones.

Adrenal cortex zones based on the hormonal synthesis ability and location:

Adrenal cortex zones - By Jpogi - https://commons.wikimedia.org/wiki/File:Adrenal_gland_%28cortex%29.JPG, CC0, https://commons.wikimedia.org/w/index.php?curid=37838551

Impairment of each pathway and enzyme may lead to a specific subtype of congenital adrenal hyperplasia include:

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes

Adrenal steroid synthesis pathways in adrenal cortex and related enzymes [1]

Summary and important Characteristics of the different congenital adrenal hyperplasia subtypes: [2][3][4]

Disease History and symptoms Laboratory findings Defective gene
Blood pressure Genitalia Cortisol Aldosterone Androgens Estrogens Increased hormone precursors Potassium levels
21-hydroxylase deficiency Classic type, salt-wasting ↓↓ Relatively low

CYP21A1 and CYP21A2 gene

Classic type, non-salt-wasting Normal
  • Male: normal or scrotal pigmentation and large phallus
Relatively low Normal CYP21A1 and CYP21A2 gene
Non-classic type Normal Normal Normal Relatively low Normal

CYP21A1 and CYP21A2 gene

17-α hydroxylase deficiency Normal corticosterone

Normal cortisol

CYP17A1
11-β hydroxylase deficiency
  • Male: Normal or scrotal pigmentation and large phallus
Relatively low CYP11B1
3 beta-hydroxysteroid dehydrogenase deficiency Male:↓

Female:↑

HSD3B2
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) Normal Normal Normal Mutations in the flavoprotein co-factor of the enzymes CYP17A1, CYP21A2, and CYP19A1 (aromatase).
Congenital lipoid adrenal hyperplasia None of precursors increased Gene mutations on chromosome 8, codes for a protein called steroid acute regulatory protein (StAR)

Differential Diagnosis

Congenital adrenal hyperplasia can present with different symptoms such as:

Differential diagnosis for each of these symptoms are described in below tables.

Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[5][6]

Disease Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[7][6][8]

Disease Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:
  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea:[9][2][3][4][10][11][12][13]

Disease Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
3 beta-hydroxysteroid dehydrogenase deficiency

Yes in female

Yes in female

Normal

Normal

XY and XX

17-alpha-hydroxylase deficiency

No

No

Normal

Normal

XY

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

XY

LH receptor defects

No

No

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY

Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

45 XO

17 alpha-hydroxylase deficiency and 11β-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):

Pseudohyperaldosteronism causes Disease Etiology Clinical features Labratory Treatment
Elevated mineralocorticoid Renin Aldosterone Other
Endogenous causes 17 alpha-hydroxylase deficiency Mutations in the CYP17A1 gene Deoxycorticosterone (DOC) Cortisol Corticosteroids
11β-hydroxylase deficiency Mutations in the CYP11B1 gene Cortisol
Apparent mineralocorticoid excess syndrome (AME) Genetic or acquired defect of 11-HSD gene Cortisol has mineralocorticoid effects Urinary free cortisone ↓↓ Dexamethasone and/or mineralocorticoid blockers
Liddle’s syndrome (Pseudohyperaldosteronism type 1) Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism Cortisol Amiloride or triamterene
Cushing’s syndrome
  • The main pathogenetic mechanism is linked to the excess

of cortisol which saturates 11-HSD2 activity,

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity) Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑
  • Adrenalectomy
Insensitivity to glucocorticoids (Chrousos syndrome) Mutations in glucocorticoid receptor (GR) gene Deoxycorticosterone (DOC) Cortisol Dexamethasone
Cortisol-secreting adrenocortical carcinoma Multifactorial

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)

Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑ Surgery
Geller’s syndrome Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR Severe hypertension particularly during pregnancy Progesterone has mineralocorticoid effects - mineralocorticoid blockers
Gordon’s syndrome (Pseudohypoaldosteronism type 2) Mutations of at least four genes have been identified, including WNK1 and WNK4
  • Normal renal function
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule Normal Hyperkalemia thiazide diuretics and/or dietary sodium restriction
Exogenous causes Corticosteroids with mineralocorticoid activity Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone, Medications such as fludrocortisone - Change the treatment
Licorice ingestion Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone - Urinary free cortisol Moderate ↑ Discontinue licorice
Grapefruit High assumption of naringenin, a component of grapefruit, can also block 11-HSD - - Discontinue grapefruit
Estrogens Estrogens can retain sodium and water by different mechanisms, causing:
  • Increased blood pressure values and suppressing the renin aldosterone system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of angiotensinogen
- - Discontinue estrogens

CAH must be differentiated from other causes of irregular menses and hirsutism:

Disease Differentiating Features
Pregnancy
  • Pregnancy always should be excluded in a patient with a history of amenorrhea
Hypothalamic amenorrhea
  • Diagnosis of exclusion
  • Seen in athletes, people on crash diets, patients with significant systemic illness, and those experiencing undue stress or anxiety
  • Predisposing features are as follows weight loss, particularly if features of anorexia nervosa are present or the BMI is <19 kg/m2
  • Recent administration of depot medroxyprogesterone, which may suppress ovarian activity for 6 months to a year
  • Use of dopamine agonists (eg, antidepressants) and major tranquilizers
  • Hyperthyroidism
  • In patients with weight loss related to anorexia nervosa, fine hair growth (lanugo) may occur all over the body, but it differs from hirsutism in its fineness and wide distribution
Primary amenorrhea
Cushing syndrome
Hyperprolactinemia
Ovarian or adrenal tumor
Congenital adrenal hyperplasia
  • Congenital adrenal hyperplasia is a rare genetic condition resulting from 21-hydroxylase deficiency
  • The late-onset form presents at or around menarche Patients have features of androgenization and subfertility
  • Affects approximately 1% of hirsute patients More common in Ashkenazi Jews (19%), inhabitants of the former Yugoslavia (12%), and Italians (6%)
  • Associated with high levels of 17-hydroxyprogesterone
  • A short adrenocorticotropic hormone stimulation test with measurement of serum17-hydroxyprogesterone confirms the diagnostic assays of a variety of androgenic hormones help define other rare adrenal enzyme deficiencies, which present similarly to 21-hydroxylase deficiency
Anabolic steroid abuse
Hirsutism
  • Hirsutism is excessive facial and body hair, usually coarse and in a male pattern of distribution
  • Approximately 10% of women report unwanted facial hair
  • There is often a family history and typically some Mediterranean or Middle Eastern ancestry
  • May also result from use of certain medications, both androgens, and others including danazol, glucocorticoids, cyclosporine, and phenytoin
  • Menstrual history is normal
  • When the cause is genetic, the excessive hair, especially on the face (upper lip), is present throughout adulthood, and there is no virilization
  • When secondary to medications, the excessive hair is of new onset, and other features of virilization, such as acne and deepened voice, may be present

References

  1. "File:Adrenal Steroids Pathways.svg - Wikimedia Commons".
  2. 2.0 2.1 Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  3. 3.0 3.1 Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  4. 4.0 4.1 Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  5. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  6. 6.0 6.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  7. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  8. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
  9. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  10. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  11. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  12. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  13. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.